TNXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy (speculative, event-driven). TNXP just released positive Phase 3 TONMYA fibromyalgia data, which is a meaningful near-term catalyst, and options positioning is strongly call-skewed—often supportive of momentum follow-through despite today’s -5.38% regular-session pullback. With price sitting near first support (S1 ~16.28) and below the pivot (17.888), the setup favors an impatient trader looking to enter on weakness for a potential bounce/re-pricing attempt toward 18–19.5 ahead of the next catalyst window (earnings 2026-02-09).
Intellectia Proprietary Trading Signals
Trend/price action: Short-term pressure (regular session -5.38%, post-market -0.93%) has pulled TNXP below the pivot level (17.888), which keeps the near-term trend cautious, but it is now closer to support where rebounds commonly start. Momentum: MACD histogram is positive (0.157) but contracting—bullish momentum exists but is weakening, consistent with a pullback after a catalyst. RSI: RSI(6) ~42 (neutral/leaning soft), not oversold yet, leaving room for either another dip or a bounce. Levels: Immediate support S1 ~16.28 (then S2 ~15.286). Immediate resistance is the pivot 17.888, then R1 ~19.496. A reclaim of 17.888 improves odds of a push toward 19–19.5; a clean break under 16.28 shifts odds toward 15.3.
Clinical catalyst: Positive Phase 3 RESILIENT data for TONMYA in fibromyalgia with statistically significant pain reduction—potentially the dominant driver for re-rating attempts.
Options sentiment: Heavy call skew + elevated volume signals risk-on speculation.
Near-term calendar: Upcoming QDEC 2025 earnings on 2026-02-09 (after hours) can act as an attention catalyst into the date.
“Sell-the-news” tape: Despite strong clinical headlines, the stock sold off in the regular session (-5.38%), implying profit-taking/overhang.
Technical position: Trading below pivot (17.
with weakening MACD momentum; failure to hold S1 (~16.
would likely invite further downside.
No supportive flow signals: Hedge fund and insider trading trends are reported neutral (no recent meaningful accumulation signals).
Latest quarter provided: 2025/Q3. Revenue grew to $3.29M (+16.58% YoY), and gross margin improved to ~58.45 (+30.18% YoY), showing better top-line and margin direction. Net income improved to -$32.01M (125.22% YoY improvement, still a loss). EPS fell to -3.59 (-84.31% YoY), indicating per-share performance remains weak despite the net loss improvement—overall: improving revenue/margins but still loss-making with mixed per-share trend.
No analyst rating/price target change data was provided, so a true ‘recent trend’ can’t be confirmed from this dataset. Practical Wall Street-style read from what is available: Pros—major Phase 3 efficacy headline can drive re-rating and renewed attention; options positioning is bullish. Cons—loss-making financial profile with weak EPS trend and today’s post-headline drawdown suggests skepticism/overhang. Politician/congress activity: no recent congress trading data available.
